A review of recent articles dealing with long-term outcomes of catheter ablation in patients with atrial fibrillation has confirmed the success rates obtained in the short period. Repetition of the ablation procedure was necessary often in a high percentage of patients. Repeat ablation as well as continued vigilance for atrial fibrillation recurrence must be considered by clinicians when discussing the pros and cons of the ablation procedure with patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2459/JCM.0b013e32834063fe | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corrigendum: Divergent electrophysiologic action of dapagliflozin and empagliflozin on ventricular and atrial tachyarrhythmias in isolated rabbit hearts.
Front Cardiovasc Med
February 2025
Department of Cardiology II, Electrophysiology, University Hospital Münster, Münster, Germany.
[This corrects the article DOI: 10.3389/fcvm.2024.
View Article and Find Full Text PDFComprehensive bioinformatics analysis of hub genes in ischemic heart failure and atrial fibrillation.
Front Cardiovasc Med
February 2025
Department of Rehabilitation, Huadong Hospital, Fudan University, Shanghai, China.
Background: Atrial fibrillation (AF) and heart failure (HF) frequently coexist and mutually influence each other. The association between AF and the subtype of HF, Ischaemic heart failure (IHF), remains insufficiently described, despite their high prevalence. Hence, comprehending their underlying pathophysiological mechanisms and identifying new therapeutic targets are urgently needed.
View Article and Find Full Text PDFIntraprocedural activated clotting time and heparin dosage in pulsed field ablation of paroxysmal atrial fibrillation.
Front Cardiovasc Med
February 2025
Department of Cardiology, Institute of Cardiovascular Diseases, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Aims: Whether the intraprocedural anticoagulation regimen and activated clotting time (ACT) in pulsed field ablation (PFA) for atrial fibrillation (AF) are the same as those for radiofrequency catheter ablation (RFCA) is currently unknown.
Methods And Results: Our retrospective study included 51 paroxysmal AF patients who underwent PFA (PFA group) and were matched with paroxysmal AF patients who underwent RFCA. Nearest-neighbor propensity score matching was performed at a 1:1 ratio (no tolerance to anticoagulant regimens and a tolerance of 0.
Cardiovascular Events During Treatment With Xanthine Oxidoreductase Inhibitors in Patients With Gout and Hyperuricemia in Japan - A JMDC Claims Database Study.
Circ Rep
March 2025
Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine Tochigi Japan.
Background: Studies have shown an increased risk of cardiovascular events during treatment with febuxostat vs. allopurinol, but comparative data with another xanthine oxidoreductase inhibitor (XORi), topiroxostat, are lacking. In this retrospective study we compared the incidence of cardiovascular/renal events in Japanese patients with newly diagnosed hyperuricemia and/or gout treated with allopurinol, febuxostat or topiroxostat.
View Article and Find Full Text PDFClinical Features of Acute on Chronic Lower Limb Ischemia and the Importance of Underlying Arterial Disease for Revascularization.
Circ Rep
March 2025
Department of Vascular Surgery, Asahikawa Medical University Hokkaido Japan.
Background: Acute lower extremity limb ischemia (ALI) is a common vascular surgery emergency, primarily caused by embolism or atherosclerotic in situ thrombosis-acute on chronic limb ischemia (AoCLI). This study aimed to examine the clinical features and treatment challenges of AoCLI.
Methods And Results: Between January 2014 and December 2022, 73 patients with AoCLI (n=35) or embolic ALI (n=38) were analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!